Metastatic Renal Cell Carcinoma ( mRCC) (DBCOND0123126)

Identifiers

Synonyms
Renal Cell Carcinoma Metastatic / Metastatic Renal Cell Carcinoma (mRCC) / Metastatic Renal Cell Carcinoma / Renal Cell Carcinoma, Metastatic / Renal Cell Cancer Metastatic / Metastatic Renal Cell Cancer / Metastatic renal cell carcinoma (morphologic abnormality) / Metastatic renal cell carcinoma (disorder)

Associated Data

Indicated Drugs and Targets
DrugDescriptionTargets
Aldesleukin
A recombinant analog of interleukin-2 used to induce an adaptive immune response in the treatment of renal cell carcinoma.
Bevacizumab
A monoclonal anti-vascular endothelial growth factor antibody used in combination with antineoplastic agents for the treatment of many types of cancer.
Medroxyprogesterone acetate
A progestin used as a contraceptive and in the treatment of secondary amenorrhea, abnormal uterine bleeding, pain from endometriosis, endometrial and renal carcinomas, paraphilia in males, and GnRH-dependent precocious puberty.
Nivolumab
A PD-1 blocking antibody used to treat melanoma, non small-cell lung cancer, renal cell cancer, head and neck cancer, and Hodgkin lymphoma.
Pembrolizumab
A PD-1 blocking antibody used to treat various types of cancer, including metastatic melanoma, non small-cell lung cancer, cervical cancer, head and neck cancer, and Hodgkin's lymphoma.
Clinical Trials
IdentifierTitleDrug(s)PurposePhaseStatus
NCT06161233
Pilot Study of the eHealth Application "Cancer Patients Better Life Experience" (CAPABLE) - ItalyNo drug interventionssupportive_careNot Availablecompleted
NCT03905889
A Study of Abemaciclib in Combination With Sunitinib in Metastatic Renal Cell Carcinomatreatment1terminated
NCT05548621
A Prospective Study to Evaluate the Implementation of Shared Decision Making Strategy for Renal Cell Cancer (RCC)No drug interventionsNot AvailableNot Availablerecruiting
NCT03699579
Pharmaco-Economic Study of Treatment Options in Patients With Advanced RCCNo drug interventionsNot AvailableNot Availablecompleted
NCT04764487
A Web-mediated Follow-up With the Web-application KidneyPRO Versus Standard Follow-up for Patients With Advanced Renal Cell Carcinoma Treated With Axitinib/Pembrolizumab in First LineNo drug interventionsprevention3recruiting
NCT03977571
Deferred Cytoreductive Nephrectomy in Synchronous Metastatic Renal Cell Carcinoma: The NORDIC-SUN-TrialNo drug interventionstreatmentNot Availablerecruiting
NCT05103722
Combined Aerobic and Resistance Exercise Training in Metastatic Renal Cell CarcinomaNo drug interventionssupportive_careNot Availableterminated
NCT06377722
Cabozantinib Treatment Prior to Cytoreductive Nephrectomy in Patients With Advanced or Metastatic Renal Cells Cancertreatment2terminated
NCT06321250
A Study of JMKX003948 Tablets in Patients With Renal Cell CarcinomaNo drug interventionstreatment1recruiting
NCT04659343
TDM for Optimized Outcome in Patients With mRCC.No drug interventionsNot AvailableNot Availablerecruiting
NCT06601296
Radiotherapy in Combination With Checkpoint Inhibition for Patients With Metastatic Kidney CancerNo drug interventionstreatment2not_yet_recruiting
NCT04115189
A Retrospective Medical Record Review of First-Line Sunitinib Administration Schedules and Outcomes Among Patients With mRCC in Latin America (LA)Not AvailableNot Availablecompleted
NCT05287464
International Multicentric Study ARON-1Not AvailableNot Availablerecruiting
NCT01390519
A Norwegian Observational Trial Evaluating the Treatment of Advanced Renal Cell Cancer Patients Under Treatment of AfinitorNo drug interventionsNot AvailableNot Availablecompleted
NCT02184416
Study Of The Impact Of Inlyta In 2nd Line On The Treatment Outcomes Of mRCC Patients Treated With Sutent In 1st Line In The Real Life SettingNo drug interventionsNot AvailableNot Availablecompleted
NCT01514448
Safety and Efficacy of Everolimus in Metastatic Renal Cell Carcinoma After Failure of First Line Therapy With Sunitinib or Pazopanibtreatment4completed
NCT04175262
Clinical Outcomes For Patients With Metastatic Renal Cell Carcinoma (mRCC) Who Received Sunitinib After 1st Line Immune-oncology (IO) TreatmentsNot AvailableNot Availablecompleted
NCT06607809
Inflammatory Markers (ICC, MCVL) and Nivolumab Response: Predicting Immunotherapy Success in Metastatic RCCNo drug interventionsNot AvailableNot Availablecompleted
NCT03055013
Nivolumab in Treating Patients With Localized Kidney Cancer Undergoing Nephrectomytreatment3active_not_recruiting
NCT04514484
Testing the Combination of the Anti-cancer Drugs XL184 (Cabozantinib) and Nivolumab in Patients With Advanced Cancer and HIVtreatment1active_not_recruiting
NCT03595124
A Study to Compare Treatments for a Type of Kidney Cancer Called TFE/Translocation Renal Cell Carcinoma (tRCC)treatment2active_not_recruiting
NCT03647878
Study of Cabozantinib as Monotherapy or in Combination With Nivolumab in Patients With Advanced or Metastatic Renal Cell Carcinoma Under Real-life Clinical Setting in 1st Line Treatment.No drug interventionsNot AvailableNot Availablerecruiting
NCT05092373
Phase I Study of Tumor Treating Fields (TTF) in Combination With Cabozantinib or With Pembrolizumab and Nab-Paclitaxel in Patients With Advanced Solid Tumors Involving the Abdomen or Thoraxtreatment1recruiting
NCT05155033
Phase II Trial of Combination Anti-PD-1 and Aldesleukin for Metastatic Melanoma and Renal Cell Carcinomatreatment2recruiting
NCT06626256
STIL101 for Injection for the Treatment of Locally Advanced, Metastatic or Unresectable Pancreatic Cancer, Colorectal Cancer, Renal Cell Cancer, Cervical Cancer and Melanomatreatment1not_yet_recruiting
NCT04588246
Testing the Addition of Whole Brain Radiotherapy Using a Technique That Avoids the Hippocampus to Stereotactic Radiosurgery in People With Cancer That Has Spread to the Brain and Come Back in Other Areas of the Brain After Earlier Stereotactic Radiosurgerytreatment3terminated
NCT04974671
Trial of Stereotactic Body Radiation Therapy (SBRT) for Oligoprogression on Immune Checkpoint Inhibitors (ICI) in Metastatic Renal Cell CarcinomaNo drug interventionstreatment2recruiting
NCT05263050
Trial of an Alternative Cabozantinib Dosing Schedule in Metastatic Renal Cell Carcinoma and Neuroendocrine Tumorstreatment2recruiting
NCT06228326
A Study Assessing KB707 for the Treatment of Advanced Solid Tumor Malignancies Affecting the LungsNo drug interventionstreatment1recruiting
NCT06284564
A Phase II Study Bolstering Outcomes by Optimizing Immunotherapy Strategies With Evolocumab and Nivolumab in Patients With Metastatic Renal Cell Carcinoma (BOOST-RCC)treatment2recruiting
NCT04467021
Cancer and Blood Pressure Management, CARISMA StudyNo drug interventionstreatmentNot Availableactive_not_recruiting
NCT02089802
Optimizing Pazopanib Exposure in RCC Patientstreatment2terminated
NCT03541902
Cabozantinib or Sunitinib Malate in Treating Participants With Metastatic Variant Histology Renal Cell Carcinomatreatment2active_not_recruiting
NCT02187302
CRLX101(NLG207) in Combination With Bevacizumab for Metastatic Renal Cell Carcinoma (mRCC) Versus Standard of Care (SOC)treatment2completed
NCT01517243
Phase II Study of Alternating Sunitinib and Temsirolimustreatment2completed
NCT04076787
Clinical Outcomes for Patients With Renal Cell Carcinoma Who Received First-Line SunitinibNot AvailableNot Availablecompleted
NCT02056587
Everolimus in Patients With Metastatic Renal Cell Carcinoma Following Progression on Prior Bevacizumab Treatmenttreatment4completed
NCT00930033
Clinical Trial to Assess the Importance of NephrectomyNo drug interventionstreatment3completed
NCT01827254
Sutent Rechallenge In mRCC PatientsNo drug interventionsNot AvailableNot Availablecompleted
NCT02926053
TIL Therapy for Metastatic Renal Cell Carcinomatreatment1unknown_status
NCT06132945
A Study of Cabozantinib and Nivolumab With Radiation Therapy for People With Renal Cell Carcinoma That Has Spread to the Braintreatment1recruiting
NCT04712305
Urine Omics Predicting IO Therapy Responses in mRCC PatientsNo drug interventionsNot AvailableNot Availablerecruiting
NCT02330783
Efficacy and Safety of Bevacizumab Plus Sorafenib for the Third-line Treatment in Metastatic Renal Cancer Patientstreatment2unknown_status
NCT05700461
Drug Screening Using Novel IMD in Renal Cell CarcinomaNo drug interventionstreatment1recruiting
NCT03071328
INJECT: A Pilot Study of Intra-tumoral Injections in Metastatic Urological Cancersother0completed
NCT01444807
Evaluate the Efficacy of Sorafenib in Renal Cell Carcinoma Patients After a Radical Resection of the Metastasestreatment2unknown_status
NCT00630409
Phase II Clinical Trial of Gemcitabine and Doxil® for Metastatic Renal Cell Carcinomatreatment2completed
NCT01482156
Dose Finding Study of RAD001 (Everolimus, Afinitor®) in Combination With BEZ235 in Patients With Advanced Solid Tumorstreatment1completed
NCT00554515
The High-Dose Aldesleukin (IL-2) "Select" Trial for Patients With Metastatic Renal Cell Carcinomatreatment2completed
NCT00142415
Phase I/II Dose-escalation Study of Lutetium-177-labeled cG250 in Patients With Advanced Renal Cancertreatment1 / 2completed
NCT01266837
Open Label, Single Arm Trial to Characterize Patients With Metastatic RCC Treated With Everolimus After Failure of the First VEGF-targeted Therapy (MARC-2)treatment4completed
NCT02789137
Study On Fatigue- And Hand-Foot Syndrome-Related Quality Of Life In Patients With Metastatic Renal Cell Carcinoma Receiving A Tyrosine Kinase Inhibitor as First-Line TreatmentNo drug interventionsNot AvailableNot Availablecompleted
NCT01202032
Multicenter Dose-escalation Study of a Combination of Pazopanib and Bevacizumab in Patients With Metastatic Renal Cell Carcinoma or Others Advanced Solid Tumorstreatment1completed
NCT02398552
A Phase II Trila of Sunitinib Schedule 4/2 vs. Shedule 2/1 as First Line Therapy in Metastatic Renal Cell Carcinoma.treatment2unknown_status
NCT03149159
Investigator-Initiated Trial of Combined Ipilimumab, Nivolumab and Stereotactic Radiation in Patients With Metastatic Clear-Cell RCC (ccRCC) Who Have Failed Treatment With Single-Agent Nivolumabtreatment2withdrawn
NCT02298959
Testing the PD-1 Antibody, MK3475, Given With Ziv-aflibercept in Patients With Advanced Cancertreatment1active_not_recruiting
NCT01481870
Comparison of Sequential Therapies With Sunitinib and Sorafenib in Advanced Renal Cell Carcinomatreatment3unknown_status
NCT04337970
Talazoparib and Axitinib for People With Previously Treated Advanced Kidney Cancertreatment1 / 2active_not_recruiting
NCT01100242
Velcade and Sorafenib in Unresected or Metastatic Renal Cell Carcinomatreatment2terminated
NCT01182142
Study of Capecitabine in Metastatic Non-clear Cell Renal Cell Carcinoma (RCC) Patientstreatment2completed
NCT03519542
Epidemiological Study to Identify Prognosis and Predictive Biomarkers for Advanced or Metastatic Renal Cell CarcinomaNot AvailableNot Availablecompleted
NCT05858749
A Study to Learn About the First and Later Lines of Medicines in Treating People With Metastatic Renal Cell Carcinoma (mRCC).No drug interventionsNot AvailableNot Availablecompleted
NCT02595918
Nivolumab in Treating Patients With High-Risk Kidney Cancer Before Surgerytreatment1terminated
NCT05259319
Study Evaluating the Safety and the Efficacy of Combination of Atezolizumab, Tiragolumab and and Stereotactic Body Radiation Therapy in Patients With Oligometastatic Multiorgan (IMMUNOs-SBRT)treatment1recruiting
NCT00740441
A Phase II Study of AS1411 in Renal Cell Carcinomatreatment2unknown_status
NCT02944617
Probiotic Yogurt Supplement in Reducing Diarrhea in Patients With Metastatic Kidney Cancer Being Treated With Vascular Endothelial Growth Factor-Tyrosine Kinase InhibitorNo drug interventionssupportive_careNot Availablecompleted
NCT01525017
A Clinical Study to Evaluate Safety and Immunologic Response of COMBIG-DC, in Patients With Metastatic Kidney CancerNo drug interventionstreatment1completed
NCT02599324
Study to Evaluate Ibrutinib Combination Therapy in Patients With Selected Gastrointestinal and Genitourinary Tumorstreatment1 / 2completed
NCT03494816
Study of Axitinib for Reducing Extent of Venous Tumour Thrombus in Renal Cancer With Venous Invasiontreatment2completed
NCT02035358
Immunotherapy Study for Metastatic Renal Cell CancerNo drug interventionstreatment1completed
NCT02849535
Impact of the PRISM-care Multidisciplinary Oncology Program on Secured Drug Intake of Patients With Kidney CancerNo drug interventionssupportive_careNot Availableunknown_status
NCT05119335
A Study of NKT2152, a HIF2α Inhibitor, in Patients With Advanced Clear Cell Renal Cell CarcinomaNo drug interventionstreatment1 / 2recruiting
NCT01977586
Functional Imaging in the Assessment of mRCC Response to SunitinibNo drug interventionsdiagnosticNot Availablewithdrawn
NCT01673386
A Subject Treatment Preference Study of Tivozanib Versus Sunitinib in Subjects With Metastatic RCCtreatment2terminated
NCT03589339
NBTXR3 Activated by Radiotherapy for Patients With Advanced Cancers Treated With An Anti-PD-1 Therapytreatment1recruiting
NCT03927248
PAC-1 for Treatment of Refractory, Metastatic Kidney Cancertreatment1 / 2withdrawn
NCT04140526
Safety, PK and Efficacy of ONC-392 in Monotherapy and in Combination of Anti-PD-1 in Advanced Solid Tumors and NSCLCtreatment1 / 2recruiting
NCT00203866
Trial of G250 Peptide and IL-2 Following Surgical Resection of Locally Advanced/Metastatic Renal Cell CarcinomaNo drug interventionstreatment2terminated
NCT04603365
Pamiparib and Temozolomide for the Treatment of Hereditary Leiomyomatosis and Renal Cell Cancertreatment2withdrawn
NCT03091465
Validation of the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) Prognostic Classification for Targeted Therapies (TKI/mTOR Inhibitors) in Second Line After First Line Treatment With PazopanibNo drug interventionsNot AvailableNot Availablecompleted
NCT04961320
Occupational Therapy Fatigue Management-Based Intervention for Metastatic Renal Cell CarcinomaNo drug interventionssupportive_careNot Availablewithdrawn
NCT04068831
Talazoparib and Avelumab in Participants With Metastatic Renal Cell Carcinomatreatment2completed
NCT01274273
Study of Interleukin-2, Interferon-alpha and Bevacizumab in Metastatic Kidney Cancertreatment2unknown_status
NCT01223027
Study of Dovitinib Versus Sorafenib in Patients With Metastatic Renal Cell Carcinomatreatment3completed
NCT05112627
Immunophenotyping in Metastatic Kidney Cancer Patients Receiving Ablative TherapyNo drug interventionsNot AvailableNot Availablecompleted
NCT04262427
The CAPER Trial: A Phase Ib Clinical Trial of Cyclophosphamide And PEmbrolizumab in Metastatic Renal Cell Carcinomatreatment1 / 2unknown_status
NCT03140176
Real-world Clinical Patterns Of Care And Outcomes Among AfME mRCC Patients Receiving Sunitinib as First Line Therapy.Not AvailableNot Availableterminated
NCT00357760
Ziv-Aflibercept in Treating Patients With Metastatic or Unresectable Kidney Cancertreatment2completed
NCT01689662
Safety and Efficacy of FolateScan (Technetium Tc 99m EC20) in Subjects With Suspected Metastatic Renal Cell CarcinomaNo drug interventionsother2completed
NCT03587662
Ixazomib, Gemcitabine, and Doxorubicin in Treating Patients With Locally Advanced or Metastatic Kidney Cancertreatment2active_not_recruiting
NCT01073644
Post Marketing Surveillance On The Safety And Tolerability Of Sunitinib Malate (Sutent) For Filipino PatientsNot AvailableNot Availableterminated
NCT04049344
Decitabine Combined With Oxaliplatin in Patients With Advanced Renal Cell Carcinomatreatment2unknown_status
NCT01415167
PROCLAIM Registry to Evaluate the Treatment Patterns and Clinical Response in MalignancyNo drug interventionsNot AvailableNot Availablecompleted
NCT03115801
A Phase II Randomized Trial of Immunotherapy Plus Radiotherapy in Metastatic Genitourinary Cancerstreatment2terminated
NCT01152801
Safety of RAD001 in Chinese Patients With Metastatic Renal Cell Cancertreatment1completed
NCT01491672
Everolimus as Second-line Therapy in Metastatic Renal Cell Carcinomatreatment2completed
NCT01582672
Phase 3 Trial of Autologous Dendritic Cell Immunotherapy Plus Standard Treatment of Advanced Renal Cell Carcinomatreatment3terminated
NCT02150369
Interleukin-2-Induced Cognitive/Affective/Sleep SymptomsNo drug interventionsNot AvailableNot Availablecompleted
NCT00421512
A Phase I Study of Bevacizumab and Sunitinib in Metastatic Renal Cell Carcinoma Patientstreatment1completed
NCT05119010
A Pilot Study Evaluating a Ketogenic Diet Concomitant to Nivolumab and Ipilimumab in Patients With Metastatic Renal Cell CarcinomaNo drug interventionstreatmentNot Availablerecruiting
NCT06361810
PSMA Therapy and Immunotherapy in Kidney Cancertreatment1 / 2not_yet_recruiting
NCT00318110
Matched Unrelated Donor Transplant for Metastatic Renal Cell CarcinomaNo drug interventionstreatment2terminated
NCT04090710
SBRT With Combination Ipilimumab/Nivolumab for Metastatic Kidney Cancertreatment2active_not_recruiting
NCT05269381
Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab for Treatment of Advanced Solid Tumorstreatment1 / 2recruiting
NCT03463681
A Study of CaBozantinib in Patients With Advanced or Unresectable Renal cEll cArcinomatreatment2completed
NCT04788095
App-Based Mindfulness Intervention for the Improvement of Quality of Life in Patients With Metastatic Renal Cell CancerNo drug interventionsdevice_feasibilityNot Availableactive_not_recruiting
NCT02419495
Phase IB Study to Evaluate the Safety of Selinexor (KPT-330) in Combination With Multiple Standard Chemotherapy or Immunotherapy Agents in Patients With Advanced Malignanciestreatment1active_not_recruiting
NCT00709995
A Study for Participants With Metastatic Renal Cell Carcinomatreatment2completed
NCT00444314
Phase 2 Study of Panzem® NCD Alone and Combined With Sunitinib Malate in Patients With Metastatic Renal Cell Carcinomatreatment2completed
NCT06500455
Testing Longer Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients With Cancer That Has Spread to the BrainNo drug interventionstreatment3not_yet_recruiting
NCT01028638
Vascular Endothelial Growth Factor (VEGF) Imaging Before and During Everolimus Treatment for Renal Cell CarcinomaNo drug interventionsNot AvailableNot Availablecompleted
NCT03138538
M8891 First in Human in Solid TumorsNo drug interventionstreatment1terminated
NCT03692338
INTERVAL: Ipilimumab and Nivolumab Combination Therapy: A Study of a Supervised or Semi-Supervised Exercise InteRVention or Usual Care With Functional Capacity and Quality of Life Evaluations in Subjects With Advanced or Metastatic RenAL Cell CarcinomaNo drug interventionssupportive_careNot Availableterminated
NCT05817903
Axitinib Intensification Plus Nivolumab or Nivolumab Alone After Nivolumab Plus Ipilimumab in mRCC Patientstreatment2recruiting
NCT02122003
Second Line Sorafenib After Pazopanib in Patients With RCCtreatment2terminated
NCT02406521
Exploratory Study of Radium-223 and VEGF-Targeted Therapy in Patients With Metastatic Renal Cell Carcinoma and Bone Metstreatment1completed
NCT01577784
Pazopanib in Second-line Therapy in Renal Cell Carcinomatreatment2unknown_status
NCT02282579
Spanish Retrospective Study to Evaluate the Efficacy and Safety of Targeted Therapies After Pazopanib as First-line TherapyNot AvailableNot Availablecompleted
NCT02447887
Study of Ixazomib With Pegylated IFN-alpha 2b (pIFN) in Metastatic Renal Cell Carcinoma (mRCC)treatment1 / 2terminated
NCT01136733
A Study of E7080 Alone, and in Combination With Everolimus in Subjects With Unresectable Advanced or Metastatic Renal Cell Carcinoma Following One Prior Vascular Endothelial Growth Factor (VEGF)-Targeted Treatmenttreatment1 / 2completed
NCT02959554
Study in Which Therapy is Either Switched to Nivolumab After 3 Months of Treatment or Therapy is Continued With a Tyrosine Kinase Inhibitor in Patients With Metastatic Renal Cell Carcinoma (RCC) and Disease Controltreatment2terminated
NCT05863351
Focused Radiation Versus Systemic Therapy for Kidney Cancer Patients With Limited Metastasis, SOAR StudyNo drug interventionstreatment3recruiting
NCT01219751
Trial Of Sunitinib In Advanced Non-Clear Cell Type Renal Cell Carcinomatreatment2unknown_status
NCT04693377
Cryoablation Combined With Stereotactic Body Radiation Therapy for the Treatment of Painful Bone Metastases, the CROME TrialNo drug interventionssupportive_careNot Availablerecruiting
NCT00684645
Non-Interventional Study (NIS) In Patients With Advanced And/Or Metastatic Renal Cell Carcinoma (mRCC) Treated With SUTENT®Not AvailableNot Availablecompleted
NCT00151645
Efficacy of Activated Lymphocytes in Renal Cell Carcinoma.No drug interventionstreatment2terminated
NCT04462445
Prospective Translational Study Investigating Possible Molecular prEdictors of Resistance to First-Line pazopanIbtreatment2completed
NCT00930345
Biological, Pathological and Imagery Markers in the First-line Treatment of Metastatic Clear-cell Renal Cell Carcinomatreatment4terminated
NCT03729245
A Study of Bempegaldesleukin (NKTR-214: BEMPEG) in Combination With Nivolumab Compared With the Investigator's Choice of a Tyrosine Kinase Inhibitor (TKI) Therapy (Either Sunitinib or Cabozantinib Monotherapy) for Advanced Metastatic Renal Cell Carcinoma (RCC)treatment3terminated
NCT04510597
Comparing the Outcome of Immunotherapy-Based Drug Combination Therapy With or Without Surgery to Remove the Kidney in Metastatic Kidney Cancer, the PROBE TrialNo drug interventionstreatment3recruiting
NCT00515697
A Study of Ramucirumab in Participants With Metastatic Renal Cell Carcinomatreatment2completed
NCT03474497
UCDCC#272: IL-2, Radiotherapy, and Pembrolizumab in Patients Refractory to Checkpoint Blockadetreatment1 / 2recruiting
NCT03575611
Stereotactic Body Radiation Therapy in Treating Patients With Oligometastatic Renal Cell CarcinomaNo drug interventionstreatment2suspended
NCT03829111
CBM588, Nivolumab, and Ipilimumab in Treating Patients With Stage IV or Advanced Kidney Cancertreatment1completed
NCT00068393
Doxorubicin and Gemcitabine in Treating Patients With Locally Recurrent or Metastatic Unresectable Renal Cell Carcinomatreatment2completed
NCT01784978
Efficacy Study of Sunitinib and Everolimus (Rotational vs Sequential Arm) in Pats. With m Clear Cell Renal Cancertreatment2terminated
NCT03284385
Testing AZD1775 in Advanced Solid Tumors That Have a Mutation Called SETD2treatment2active_not_recruiting
NCT03891485
Nivolumab in mRCC Patients: Treg Function, T-cell Access and NK Interactions to Predict and Improve EfficacyNo drug interventionsNot AvailableNot Availablerecruiting
NCT02864615
Safety and Preliminary Efficacy of SBRT in Patients With Metastatic RCC Treated With Targeted or IO TherapyNo drug interventionstreatmentNot Availablecompleted
NCT05135832
Patient Reported Outcomes by Patients With Metastatic Renal Cell CarcinomaNo drug interventionssupportive_careNot Availableunknown_status
NCT02867332
PD-1 Knockout Engineered T Cells for Metastatic Renal Cell Carcinoma.treatment1withdrawn
NCT04644432
Individualized Treatment Strategy for Patients With Metastatic Non-clear Cell Renal Cell CarcinomaNo drug interventionstreatment2unknown_status
NCT03408652
Efficacy and Safety of Systemic Treatments of Bone Metastases From Kidney Cancer in Patients Treated With Targeted Therapiessupportive_care3terminated
NCT02774200
A One-arm Exploratory Clinical Research Program Study of Apatinib in Advanced Metastatic Renal Cell Carcinoma Patients.treatment2unknown_status
NCT05816642
Application Circulating Tumor DNA Dynamic Monitoring in Clinical Treatment of Metastatic Renal Cell CarcinomascreeningNot Availablerecruiting
NCT06391099
Ketogenic Dietary Intervention to Improve Response to Immunotherapy in Patients With Metastatic Melanoma and Metastatic Kidney CancerNo drug interventionssupportive_careNot Availablenot_yet_recruiting
NCT02231749
Nivolumab Combined With Ipilimumab Versus Sunitinib in Previously Untreated Advanced or Metastatic Renal Cell Carcinoma (CheckMate 214)treatment3active_not_recruiting
NCT00913913
Bevacizumab, Autologous Tumor/DC Vaccine, IL-2 and IFNα-2b in Metastatic Renal Cell Carcinoma (RCC) Patientstreatment2terminated
NCT05219318
Treatment Pause Versus Treatment Continuation in IMDC Good or Intermediate Risk With Only One Adverse Prognostic Factor in mRCC Patients With an Objective Response at 12 Months of Treatment With PD1/ PDL1 ICIs + VEGFR-Tyrosine Kinase InhibitorsNo drug interventionstreatment3recruiting
NCT06399419
CBM588 Capsules in Combination With Nivolumab and Ipilimumab for the Treatment of Advanced Stage Kidney Cancertreatment1recruiting
NCT02071641
Phase II Study of Sunitinib Rechallenge in Patients With Metastatic Renal Cell Carcinomatreatment2terminated
NCT03200717
Study of Efficacy, Safety, and Quality of Life of Pazopanib in Patients With Advanced and/or Metastatic Renal Cell Carcinoma After Prior Checkpoint Inhibitor Treatmenttreatment2completed
NCT03428217
CANTATA: CB-839 With Cabozantinib vs. Cabozantinib With Placebo in Patients With Metastatic Renal Cell Carcinomatreatment2completed
NCT00410124
RAD001 Plus Best Supportive Care (BSC) Versus BSC Plus Placebo in Patients With Metastatic Carcinoma of the Kidney Which Has Progressed After Treatment With Sorafenib and/or Sunitinibtreatment3completed
NCT04802824
Measuring Treatment Response in Metastatic Renal Cell Cancer Using FPIA PET/CTNo drug interventionsNot AvailableNot Availablerecruiting
NCT03786796
Study of Olaparib in Metastatic Renal Cell Carcinoma Patients With DNA Repair Gene Mutationstreatment2recruiting
NCT01731158
Sequential Therapy in Metastatic Renal Cell Carinomatreatment2completed
NCT00942058
Serum CA9 Level as Biological Marker of the Treatment Response in Metastatic Renal Cell CancerNo drug interventionsNot AvailableNot Availableterminated
NCT03013335
Nivolumab in Patients With Metastatic Renal Cell Carcinoma Who Have Progresses During or After Prior Systemic Anti-angiogenic Regimentreatment2completed
NCT05327686
Testing the Addition of Stereotactic Radiation Therapy With Immune Therapy for the Treatment of Patients With Unresectable or Metastatic Renal Cell Cancer, SAMURAI Studytreatment2recruiting
NCT03967522
Evaluation of Cabozantinib in Metastatic Renal Cell Carcinoma (mRCC) With Brain Metastasestreatment2recruiting
NCT03149822
Study of Pembrolizumab and Cabozantinib in Patients With Metastatic Renal Cell Carcinomatreatment1 / 2active_not_recruiting
NCT04919122
Outcomes Database to prospectivelY aSSEss the Changing TherapY Landscape in Renal Cell CarcinomaNo drug interventionsNot AvailableNot Availablerecruiting
NCT04508725
Serial Ultrasound in Metastatic Renal Cell Carcinoma (mRCC)diagnosticNot Availableactive_not_recruiting
NCT05935748
Ph2 Study NKT2152 With Palbociclib & Sasanlimab in Subjects With Advanced Clear Cell Renal Cell Carcinoma (ccRcc)treatment2recruiting
NCT00606866
MRI Study of BAY 43-9006 in Metastatic Renal Cell Carcinomatreatment3completed
NCT01689766
Study Using FolateScan to Identify Subjects With Folate Receptor-Positive Metastatic Renal Cell Carcinomaother2completed
NCT00414765
Aldesleukin in Participants With Metastatic Renal Cell Carcinoma or Metastatic Melanomatreatment4completed
NCT00570882
Study of Sunitinib Administered as 4/2 vs. 2/1 Schedule in Advanced Renal Cell Carcinoma (RCC)treatment2completed
NCT02639182
A Study of AGS-16C3F vs. Axitinib in Metastatic Renal Cell Carcinomatreatment2completed
NCT03126331
Intermittent Therapy in Metastatic Renal Cell Carcinoma Patients Treated With Ipilimumab and Nivolumabtreatment2completed
NCT05796973
Measuring Oncological Value of Exercise and Statintreatment3recruiting
NCT01342627
Sorafenib in Elderly Patients With Metastatic Renal Cell Carcinomatreatment2terminated
NCT02026960
RNA Extraction and Amplification From Biopsy Specimens in Subjects With Metastatic Renal Cell Carcinoma (AGS-NTS-017)No drug interventionsdevice_feasibilityNot Availableterminated
NCT02837991
A Dose Escalation, Safety and Activity Study of CDX-014 in Patients With Renal Cell Carcinoma and Ovarian Clear Cell CarcinomaNo drug interventionstreatment1terminated
NCT03682289
Ceralasertib (AZD6738) Alone and in Combination With Olaparib or Durvalumab in Patients With Solid Tumorstreatment2recruiting
NCT00531544
A SU011248 Expanded Access Protocol for Systemic Therapy of Patients With Metastatic Renal Cell Carcinoma Who Are Ineligible for Participation in Other SU011248 Protocols But May Derive Benefit From Treatment With SU011248treatmentNot Availablecompleted
NCT00848640
Study of Sorafenib in Patients With Advanced Renal Cell Carcinomatreatment2completed
NCT06548867
Retrospective Analysis of Patients With Metastatic Renal Cell Carcinoma Treated With CABOzantinibNot AvailableNot Availablerecruiting
NCT01550367
Study of Hydroxychloroquine and Aldesleukin in Renal Cell Carcinoma Patients (RCC)treatment1 / 2completed
NCT01265901
IMA901 in Patients Receiving Sunitinib for Advanced/Metastatic Renal Cell Carcinomatreatment3completed
NCT00619268
Combination of Temsirolimus and Bevacizumab in Patient With Metastatic Renal Cell Carcinomatreatment2completed
NCT00625768
Study of AS1409 in Patients With Either Metastatic Renal Cell Carcinoma or Metastatic Malignant Melanomatreatment1completed
NCT00291369
Cytokines in Patients With Metastatic Renal Cell Carcinoma of Intermediate Prognosistreatment3completed
NCT05122546
CBM588 in Combination With Nivolumab and Cabozantinib for the Treatment of Advanced or Metastatic Kidney Cancertreatment1active_not_recruiting
NCT04299646
Study Assessing Stereotactic Radiotherapy in Therapeutic Strategy of Oligoprogressive Renal Cell Carcinoma MetastasesNo drug interventionstreatment2recruiting
NCT03379012
Testosterone in Metastatic Renal Cell Carcinoma Patientstreatment2completed
NCT01033981
Cost Effectiveness Of Sunitinib In Central America And CaribbeanNot AvailableNot Availableterminated
NCT01441414
PF-04856884 (CVX-060) In Combination With Axitinib In Patients With Previously Treated Metastatic Renal Cell Carcinomatreatment2terminated
NCT01917214
A Retrospective Real World Analysis Of Sutent In Patients With Metastatic Renal Cell Carcinoma In Community And Academic Centers To Assess The Impact Of Dose Variation On Duration Of Response And Overall SurvivalNo drug interventionsNot AvailableNot Availablecompleted
NCT04891055
Prospective Translational Study Investigating Predictors of Outcome in Metastatic Renal Cell Carcinoma Patients Treated With Nivolumab (I-Rene Trial)No drug interventionsNot AvailableNot Availableunknown_status
NCT03075423
Randomized Phase-II Study of Nivolumab Plus Ipilimumab vs. Standard of Care in Untreated and Advanced Non-clear Cell RCCtreatment2active_not_recruiting
NCT05759923
First-in-human Phase I Study to Evaluate Safety, Tolerability and Antineoplastic Activity of OATD-02 in Patients With Selected Advanced and/or Metastatic Solid TumoursNo drug interventionstreatment1recruiting
NCT03013946
Role of PRoactivE Coaching on PAtient REported Outcome in Advanced or Metastatic RCC Treated With Sunitinib or a Combination of Pembrolizumab + Axitinib or Avelumab + Axitinib in First Line TherapyNo drug interventionssupportive_care3recruiting
NCT02974738
A Trial of Belzutifan (PT2977, MK-6482) Tablets In Patients With Advanced Solid Tumors (MK-6482-001)treatment1active_not_recruiting
NCT03562507
Multi-center Trial of ESK981 in Combination With Nivolumab in Patients With Metastatic Renal Cell Carcinomatreatment2terminated
NCT03991130
High Dose IL-2 in Combination With Anti-PD-1 to Overcome Anti-PD-1 Resistance in Metastatic Melanoma and Renal Cell Carcinomatreatment2recruiting
NCT02432846
Intratumoral Vaccination With Intuvax Pre-nephrectomy Followed by Sunitinib Post-nephrectomy vs Sunitinib Post-nephrectomy in Newly Diagnosed Metastatic Renal Cell Carcinoma (mRCC)treatment2completed
NCT06264479
Prospective Evaluation of AI R&D Tool for Patient Stratification: a Trial for Renal Immuno-oncology Model Experimental Evaluation 2No drug interventionsNot AvailableNot Availablenot_yet_recruiting
NCT05326620
National PROspective Infrastructure for Renal Cell Carcinoma (PRO-RCC)No drug interventionsNot AvailableNot Availablerecruiting
NCT04903873
A Study to Evaluate Safety, Efficacy, and Pharmacokinetics in Participants With Advanced Solid TumorsNo drug interventionstreatment1 / 2recruiting
NCT03095040
CM082 Combined With Everolimus in Chinese Patients With Metastatic Renal Cell Carcinomatreatment3unknown_status
NCT03634540
A Trial of Belzutifan (PT2977, MK-6482) in Combination With Cabozantinib in Patients With Clear Cell Renal Cell Carcinoma (ccRCC) (MK-6482-003)treatment2active_not_recruiting
NCT04749602
Intrapleural Instillation of the Nivolumab in Cancer Patients With Pleural Effusion.treatment2completed
NCT01702909
Interleukin-2 in Metastatic Kidney Cancertreatment2terminated
NCT01658813
5-Fluorouracil Followed by Interferon-alfa-2b in Previously-treated Metastatic Gastrointestinal, Kidney, or Lung Cancertreatment2completed
NCT03876925
A Single Arm, Open-label,Phase Ib Study of CT053PTSA in Preciously Treated Patients With Advanced and Metastatic RCCtreatment1 / 2terminated
NCT04368546
Sunitinib Treatment on Tissue Sodium Accumulation (TSS2)Not AvailableNot Availablecompleted
NCT01926990
Perfusion CT Monitoring to Predict Treatment Efficacy in Renal Cell CarcinomaNo drug interventionsNot AvailableNot Availablecompleted
NCT02542202
Stereotactic Body Radiation Therapy in Treating Patients With Metastatic or Recurrent Kidney CancerNo drug interventionstreatmentNot Availableterminated
NCT01884961
Radiotherapy as an Immunological Booster in Patients With Metastatic Melanoma or Renal Cell Carcinoma Treated With High-dose Interleukin-2No drug interventionstreatment2active_not_recruiting
NCT02579811
Axitinib Given on an Individualized Schedule for Metastatic Renal Cell Cancertreatment2completed
NCT02318771
Radiation Therapy and MK-3475 for Patients With Recurrent/Metastatic Head and Neck Cancer, Renal Cell Cancer, Melanoma, and Lung Cancertreatment1completed
NCT02899078
Ibrutinib and Nivolumab in Treating Patients With Previously-Treated Metastatic Kidney Cancertreatment1 / 2completed
NCT02843607
Combination of Cryosurgery and NK Immunotherapy for Advanced Kidney CancerNo drug interventionstreatment1 / 2completed
NCT01767636
Pazopanib Hydrochloride in Treating Patients With Metastatic Kidney Cancertreatment2active_not_recruiting
NCT01829841
A Study of Famitinib in Patients With Advanced Metastatic Renal Cell Cancertreatment2completed
NCT02626130
Tremelimumab With or Without Cryoablation in Treating Patients With Metastatic Kidney Cancertreatment0completed
NCT01258348
A Phase 1b Trial in Patients With Renal Cell Cancertreatment1completed
NCT01522820
Vaccine Therapy With or Without Sirolimus in Treating Patients With NY-ESO-1 Expressing Solid Tumorstreatment1completed
NCT00027820
Total-Body Irradiation and Fludarabine Phosphate Followed by Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies or Kidney Cancertreatment1 / 2completed
NCT02599194
18F-FSPG PET/CT for Cancer Patients on Therapydiagnostic2completed
NCT01462214
Study of Everolimus and Low-dose Cyclophosphamide in Patients With Metastatic Renal Cell Cancertreatment1 / 2completed
NCT02664883
Myeloid Derived Suppressor Cells Clinical Assay in Finding Kidney CancerNo drug interventionsNot AvailableNot Availableactive_not_recruiting
NCT03229278
Trigriluzole With Nivolumab and Pembrolizumab in Treating Patients With Metastatic or Unresectable Solid Malignancies or Lymphomatreatment1completed
NCT03092856
Axitinib With or Without Anti-OX40 Antibody PF-04518600 in Treating Patients With Metastatic Kidney Cancertreatment2active_not_recruiting
NCT00655252
Expanded Access Study of RAD001 in Metastatic Renal Cell Cancer Patients Who Are Intolerant of or Who Have Failed Despite Prior Vascular Endothelial Growth Factor TherapyNot AvailableNot Availableno_longer_available
NCT02089334
Dose-Finding, Safety and Efficacy Study of RX-0201 Plus Everolimus in Metastatic Renal Cell Cancertreatment1 / 2terminated
NCT00670748
Chemotherapy Followed by ESO-1 Lymphocytes and Aldesleukin to Treat Metastatic Cancertreatment2terminated
NCT02555748
Therapeutic Drug Monitoring of Sunitinib and Pazopanib in Advanced or Metastatic Renal Cell Carcinomaother4completed
NCT00428220
A Continuation Study Using Sunitinib Malate For Patients Leaving Treatment On A Previous Sunitinib Study.treatmentNot Availablecompleted
NCT02689167
Study to Assess Various Sunitinib Schedules in Renal Cell Carcinomatreatment2unknown_status
NCT01743469
A Study With Tasquinimod Treating Patients With Hepatocellular, Ovarian, Renal Cell and Gastric Cancerstreatment2completed
NCT01590069
Aerosolized Aldesleukin in Treating Patients With Lung Metastasestreatment1active_not_recruiting
NCT01246843
Evaluation of Cognitive Function of Patients With Sunitinib or SorafenibNo drug interventionsNot AvailableNot Availablecompleted